Related Experiment Videos

Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with

Niels H Buus1, Morten Bøttcher, Claus G Jørgensen

  • 1Centre for Clinical Pharmacology, Aarhus University Hospital, Aarhus C, Denmark. nhb@farm.au.dk

Insights

Angiotensin-converting enzyme (ACE) inhibition improved coronary reserve and reversed structural changes in hypertensive patients, unlike beta-blockade. This suggests vasodilating treatments may better repair hypertensive microcirculation damage.

Area of Science:

  • Cardiology
  • Pharmacology
  • Vascular Biology

Background:

  • Hypertension is linked to reduced coronary vasodilatory capacity due to structural changes in coronary resistance vessels.
  • The potential for vasodilating treatments to correct these structural abnormalities is a key area of investigation.

Purpose of the Study:

  • To compare the long-term effects of angiotensin-converting enzyme (ACE) inhibition versus beta-blockade on coronary reserve and cardiovascular structure in patients with essential hypertension.
  • To determine if vasodilating treatment offers superior benefits in repairing hypertensive microcirculation.

Main Methods:

  • A double-blind, randomized study involving 30 hypertensive patients treated for 1 year with either perindopril (an ACE inhibitor) or atenolol (a beta-blocker).
  • Measurements included cardiac output, left ventricular mass (echocardiography), resistance artery structure, and myocardial perfusion (positron emission tomography) at rest and during hyperemia.
  • Patients were compared to normotensive controls.

Main Results:

  • Perindopril significantly reduced left ventricular mass, peripheral vascular resistance, and resistance artery media thickness-to-lumen ratio.
  • Atenolol showed no significant effect on these structural parameters.
  • While both treatments reduced resting myocardial perfusion, only atenolol significantly reduced hyperemic myocardial perfusion, leading to a higher coronary reserve with perindopril.

Conclusions:

  • ACE inhibition, compared to beta-blockade, enhances coronary reserve and promotes regression of structural changes in hypertensive resistance arteries and left ventricular hypertrophy.
  • Vasodilating treatments, such as ACE inhibitors, may be more effective than non-vasodilating treatments in restoring hypertensive myocardial microcirculation.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...